EirGen Pharma Registers Oncology Product Eir-073 with PMDA
EirGen Pharma are pleased to announce that their oncology molecule Eir-073 was submitted to the PMDA (Japan) in August 2011. This product was successful developed as a treatment for advanced breast cancer for the Japanese marketplace having successfully passed fed & fasted clinical trial studies in Japan in Q1 2011, and adds to the growing portfolio of successful clinical trial oncology products for the global market.
EirGen Pharma is a pharmaceutical company based in Waterford, Ireland. Using its purpose built high containment facility; the company specialises in the development, registration and manufacture of high potency solid dose products for global markets.